Intra-Cellular Therapies Gets a Buy Rating from Cantor Fitzgerald


Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ: ITCI) today and set a price target of $28. The company’s shares opened today at $22.15.

Tanner said:

“: We are reiterating the Overweight rating and $28 PT for ITCI stock. The pharmacologic versatility of lead drug candidate lumateperone could create significant share value, in our view, if approved only for the treatment schizophrenia. The commercial opportunity could expand significantly, we believe, if lumateperone is proven to be safe and effective for bipolar depression and/or agitation associated with dementia.”

According to TipRanks.com, Tanner is a 4-star analyst with an average return of 9.5% and a 57.4% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Aquinox Pharmaceuticals.

Intra-Cellular Therapies has an analyst consensus of Strong Buy, with a price target consensus of $28.

See today’s analyst top recommended stocks >>

Based on Intra-Cellular Therapies’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.48 million. In comparison, last year the company had a GAAP net loss of $26.93 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, I

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts